tbuckley/cabot-search huggingface dataset:
Ambient Air Pollution Exposure and Outcomes in Patients Receiving Lung Transplant
Authors: Olawale Amubieya, Sam Weigt, Michael Y. Shino, Nicholas J. Jackson, John Belperio, Michael K. Ong, Keith Norris
Journal: JAMA Network Open (2024)

Importance Elevated ambient fine particulate matter (PM 2.5 ) air pollution exposure has been associated with poor health outcomes across several domains, but its associated outcomes among lung transplant recipients are poorly understood. Objective To investigate whether greater PM 2.5 exposure at the zip code of residence is associated with a higher hazard for mortality and graft failure in patients with lung transplants. Design, Setting, and Participants This retrospective cohort study used panel data provided by the United Network for Organ Sharing, which includes patients receiving transplants across all active US lung transplant programs. Adult patients who received lung transplants between May 2005 and December 2016 were included, with a last follow-up of September 10, 2020. Data were analyzed from September 2022 to May 2023. Exposure Zip code–level annual PM 2.5 exposure was constructed using previously published North American estimates. Main Outcomes and Measures The primary outcome was time to death or lung allograft failure after lung transplant. A gamma shared frailty Cox proportional hazards model was used to produce unadjusted and adjusted hazard ratios (HRs) to estimate the association of zip code PM 2.5 exposure at the time of transplant with graft failure or mortality. Results Among 18 265 lung transplant recipients (mean [SD] age, 55.3 [13.2] years; 7328 female [40.2%]), the resident zip code’s annual PM 2.5 exposure level was greater than or equal to the Environmental Protection Agency (EPA) standard of 12μg/m 3 for 1790 patients (9.8%) and less than the standard for 16 475 patients (90.2%). In unadjusted analysis, median graft survival was 4.87 years (95% CI, 4.57-5.23 years) for recipients living in high PM 2.5 areas and 5.84 years (95% CI, 5.71-5.96 years) for recipients in the low PM 2.5 group. Having an annual PM 2.5 exposure level greater than or equal to the EPA standard 12 μg/m 3 was associated with an increase in the hazard of death or graft failure (HR, 1.11; 95% CI, 1.05-1.18; P &amp;amp;lt; .001) in the unadjusted analysis and after adjusting for covariates (HR, 1.08; 95% CI, 1.01-1.15; P = .02). Each 1 μg/m 3 increase in exposure was associated with an increase in the hazard of death or graft failure (adjusted HR, 1.01; 95% CI, 1.00-1.02; P = .004) when treating PM 2.5 exposure as a continuous variable. Conclusions and Relevance In this study, elevated zip code–level ambient PM 2.5 exposure was associated with an increased hazard of death or graft failure in lung transplant recipients. Further study is needed to better understand this association, which may help guide risk modification strategies at individual and population levels.
Neuropeptide therapeutics to repress lateral septum neurons that disable sociability in an autism mouse model
Authors: Amélie M Borie, Yann Dromard, Prabahan Chakraborty, Pierre Fontanaud, Emilie M Andre, Amaury François, Pascal Colson, Françoise Muscatelli, Gilles Guillon, Michel G Desarménien, Freddy Jeanneteau
Journal: Cell Reports Medicine (2024)

Confronting oxytocin and vasopressin deficits in autism spectrum disorders and rare syndromes brought promises and disappointments for the treatment of social disabilities. We searched downstream of oxytocin and vasopressin for targets alleviating social deficits in a mouse model of Prader-Willi syndrome and Schaaf-Yang syndrome, both associated with high prevalence of autism. We found a population of neurons in the lateral septum-activated on termination of social contacts-which oxytocin and vasopressin inhibit as per degree of peer affiliation. These are somatostatin neurons expressing oxytocin receptors coupled to GABA-B signaling, which are inhibited via GABA-A channels by vasopressin-excited GABA neurons. Loss of oxytocin or vasopressin signaling recapitulated the disease phenotype. By contrast, deactivation of somatostatin neurons or receptor signaling alleviated social deficits of disease models by increasing the duration of contacts with mates and strangers. These findings provide new insights into the treatment framework of social disabilities in neuropsychiatric disorders.
Disrupting stroke-induced GAT-1-syntaxin1A interaction promotes functional recovery after stroke
Authors: Yu-Hui Lin, Feng Wu, Ting-You Li, Long Lin, Fan Gao, Li-Juan Zhu, Xiu-Mei Xu, Ming-Yu Chen, Ya-Lan Hou, Chang-Jing Zhang, Hai-Yin Wu, Lei Chang, Chun-Xia Luo, Ya-Juan Qin, Dong-Ya Zhu
Journal: Cell Reports Medicine (2024)

Although stroke is a frequent cause of permanent disability, our ability to promote stroke recovery is limited. Here, we design a small-molecule stroke recovery promoting agent that works by dissociating γ-aminobutyric acid (GABA) transporter 1 (GAT-1) from syntaxin1A (Synt1A), a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein. Stroke induces an increase in GAT-1-Synt1A interaction in the subacute phase, a critical period for functional recovery. Uncoupling GAT-1-Synt1A reverses stroke-induced GAT-1 dysfunction and cortical excitability decline and enhances synaptic GABAergic inhibition and consequently cortical oscillations and network plasticity by facilitating the assembly of the SNARE complex at the synapse. Based on the molecular mechanism of GAT-1 binding to Synt1A, we design GAT-1-Synt1A blockers. Among them, ZLQ-3 exhibits the greatest potency. Intranasal use of ZLQ-3-1, a glycosylation product of ZLQ-3, substantially lessens impairments of sensorimotor and cognitive functions in rodent models. This compound, or its analogs, may serve as a promoting agent for stroke recovery.
Integrating priorities at the intersection of cancer and neuroscience
Authors: William L Hwang, Ella N Perrault, Alexander Birbrair, Brandi J Mattson, David H Gutmann, Donald J Mabbott, Edna Cukierman, Elizabeth A Repasky, Erica K Sloan, Hui Zong, Ihsan Ekin Demir, Jami L Saloman, Jeremy C Borniger, Jian Hu, Jorg Dietrich, Joshua J Breunig, Kaan Çifcibaşı, Khalil Ali Ahmad Kasm, Manuel Valiente, Max Wintermark, Munjal M Acharya, Nicole N Scheff, Nisha J D'Silva, Paola D Vermeer, Richard J Wong, Sebastien Talbot, Shawn L Hervey-Jumper, Timothy C Wang, Yi Ye, Yuan Pan, Yuri L Bunimovich, Moran Amit
Journal: Cancer Cell (2024)
Vaginal lactobacilli produce anti-inflammatory β-carboline compounds
Authors: Virginia J Glick, Cecilia A Webber, Lauren E Simmons, Morgan C Martin, Maryam Ahmad, Cecilia H Kim, Amanda N D Adams, Sunghee Bang, Michael C Chao, Nicole C Howard, Sarah M Fortune, Manasvi Verma, Marco Jost, Lalit K Beura, Michael J James, Seo Yoon Lee, Caroline M Mitchell, Jon Clardy, Ki Hyun Kim, Smita Gopinath
Journal: Cell Host & Microbe (2024)
Leveraging genomes to support conservation and bioeconomy policies in a megadiverse country
Authors: Sibelle Torres Vilaça, Amanda F Vidal, Ana Carolina D'Oliveira Pavan, Bruno Marques Silva, Carolina S Carvalho, Cintia Povill, Danielle Luna-Lucena, Gisele L Nunes, Henrique Vieira Figueiró, Izabela Santos Mendes, Jose Augusto P Bittencourt, Lara Gomes Côrtes, Lucas Eduardo Costa Canesin, Renato R M Oliveira, Roberta P Damasceno, Santelmo Vasconcelos, Silvia B Barreto, Valeria Tavares, Guilherme Oliveira, Amely Branquinho Martins, Alexandre Aleixo
Journal: Cell Genomics (2024)
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Authors: Minjie Fu, Jiaxu Zhao, Licheng Zhang, Zhewei Sheng, Xiaohui Li, Fufang Qiu, Yuan Feng, Muyuan You, Hao Xu, Jinsen Zhang, Rui Zeng, Yang Huang, Cheng Li, Wenhan Chen, Zheng Chen, Haibao Peng, Longzhi Li, Yonghe Wu, Dan Ye, Yudan Chi, Wei Hua, Ying Mao
Journal: Cancer Cell (2024)
Reply: HKDC1 promotes liver cancer stemness under hypoxia via stabilizing β-catenin
Authors: Liqin Zhu
Journal: Hepatology (2024)

Department of Pharmacy and Pharmaceutical Sciences Correspondence Department of Pharmacy and Pharmaceutical Sciences St. Jude Children's Research Hospital 262 Danny Thomas Place I5304A, MS 313, Thomas Tower Memphis, TN 38105-3678. Email: [email protected]
Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
Authors: Anne Marie Rosendahl Madsen, Lise Gehrt, Frederik Schaltz-Buchholzer, Sören Möller, Rikke Christiansen, Lars Schellerup, Lene Annette Norberg, Tyra Grove Krause, Sebastian Nielsen, Mette Bliddal, Peter Aaby, Christine Stabell Benn
Journal: Journal of Infection (2024)
Genomic landscape of circulating tumor DNA and real-world outcomes in advanced endometrial cancer
Authors: Pamela Soberanis Pina, Keelia Clemens, Adrian Bubie, Brooke Grant, Ginger Haynes, Nicole Zhang, Leylah Drusbosky, Stephanie Lheureux
Journal: Clinical Cancer Research (2024)

ctDNA is a novel technique extensively studied in solid tumors, although not currently well defined in endometrial cancer (EC).
Spatial Dynamics of T and B Cell Response Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Authors: Yutaka Kurebayashi, Katsutoshi Sugimoto, Hanako Tsujikawa, Kosuke Matsuda, Rui Nomura, Akihisa Ueno, Yohei Masugi, Ken Yamazaki, Kathryn Effendi, Hirohito Takeuchi, Takao Itoi, Yasushi Hasegawa, Yuta Abe, Minoru Kitago, Hidenori Ojima, Michiie Sakamoto
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear. Experimental Design: We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed. Results: We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions. Conclusions: We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
Lung Ultrasound Score, Severity of Acute Lung Disease and Prolonged Mechanical Ventilation in Children
Authors: Ignacio Oulego-Erroz, María del Pilar De Castro-Vecino, Rafael González-Cortés, Almudena Alonso-Ojembarrena, Antonio Rodríguez-Nuñez, Daniel Palanca-Arias, Úrsula Quesada-Ortega, Sonia Sanchiz-Cardenas, María Ángeles Murillo-Pozo, Jorge López-González, Pilar Sánchez-Yáñez, Juan Valencia-Ramos, Andrea Fernández-de la Ballina, Nuria Chaves-Caro, Raúl Borrego-Domínguez, María Sánchez-Porras, Manuel Rodríguez-Martínez, Pedro José Carballo-Martín, Lorena Bermúdez-Barrezueta, Javier Rodríguez-Fanjul, Ana Vivanco-Allende, Patricia Rodríguez-Campoy, Laia Vega-Puyal, Javier Gil-Antón, Idoia Sánchez-Martínez, Olivia Pérez-Quevedo, Marta Muñoyerro-Sesmero, Luisa Barón-González de Suso, Juan Mayordomo-Colunga
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Lung ultrasound may be useful for prognostication of acute lung disease.
Neoadjuvant intratumoral plasmid interleukin-12 electro-gene-transfer and nivolumab in patients with operable locoregionally advanced melanoma
Authors: Ahmad A. Tarhini, Zeynep Eroglu, Islam Eljilany, Jonathan S. Zager, Ricardo J. Gonzalez, Amod A. Sarnaik, Carl Wayne Cruse, Nikhil I. Khushalani, Deanryan B. De Aquino, Edith Abraham, Diana M. Acevedo, Allison Richards, Michael J. Schell, Denise Kalos, Pei-Ling Chen, Jane L. Messina, David A. Canton, Vernon K. Sondak
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Intratumoral tavokinogene telseplasmid delivered by electroporation (TAVO-EP) results in localized expression of IL-12 within the tumor microenvironment (TME). This study evaluated neoadjuvant TAVO-EP combined with intravenous nivolumab followed by surgery and adjuvant nivolumab in patients with operable, locoregionally advanced melanoma. Patients and Methods: The neoadjuvant phase comprised up to 3 × 4-week cycles during which TAVO-EP was given intratumorally on days 1, 8, and 15 (optional) concurrently with 480 mg nivolumab intravenously on day 8 of each 4-week cycle. Surgery followed, and adjuvant nivolumab was initiated after surgery. The primary endpoint was pathologic complete response (pCR). Secondary endpoints included major pathologic response (MPR; pCR or near pCR). Results: Sixteen patients were enrolled, and the preoperative radiological response rate was 63%. One patient declined surgery after experiencing a significant clinical response. Among the remaining 15 patients, the pCR rate was 60% and the MPR was 80%. No patient with MPR has had disease recurrence with a median follow-up from the date of surgery of 15.4 months. At baseline, most patients exhibited low CD8+ tumor-infiltrating lymphocytes, PD-L1, and IFN-γ gene expression signature. There was enhanced immune activation following treatment in the TME and blood, including increased immune-related gene expression, CD8+ tumor-infiltrating lymphocytes, and proliferating immune cell subsets. Conclusions: The clinical efficacy of neoadjuvant intratumoral TAVO-EP + nivolumab is promising with 80% of patients achieving an MPR. Evidence of potent immune activation both systemically and within the TME along with a favorable safety profile supports the activity of local IL-12 and anti–PD-1 based regimens.
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
Authors: Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea, John M. Schallenkamp, Nabil Adra, Leonard J. Appleman, Mitchell Alden, Jessica Thomes Pepin, John A. Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M. Rampurwala, William R. Robinson, Hye Sung Kim, Liam Il-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research (2024)

Abstract Purpose: The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored. Patients and Methods: Dual anti–CTLA-4 and anti–PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti–CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti–PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomes were progression-free survival (PFS), overall survival, clinical benefit rate [stable disease (SD) ≥6 months plus ORR], and toxicity. Results: Seventeen patients (median age: 64; number of prior therapies ranged from 0 to 8 with no immunotherapy exposure; eight granulosa, six carcinosarcomas, one Sertoli–Leydig, one yolk sac, and one Wolffian) were evaluated. In granulosa cell tumors, ORR was 25% (n = 2/8; one CR and one PR) and clinical benefit rate was 50% (n = 4/8); PFS was 58.3 (CR), 50.7+ (PR), 30.4 (SD), and 8.7 (SD) months. Median PFS was 3.5 months [95% confidence interval, 1.7–11.2 months]; median overall survival was 42.5 months (95% confidence interval, 10.1 months–not reached). One Sertoli–Leydig cell tumor showed a 22% regression (PFS, 11.2 months). Carcinosarcomas had no response. Three participants (18%) discontinued treatment due to grade 3 to grade 4 adverse events. Conclusions: Ipilimumab–nivolumab shows activity in treatment-refractory granulosa cell tumors, with 25% (n = 2/8) of patients experiencing either CR or PR lasting more than 4 years.
Reply: Clonally expanded CD8+ T cells in MASH – invited guest overstaying their welcome
Authors: Abbigayl E.C. Burtis, Matthew A. Burchill
Journal: Hepatology (2024)

1Department of Medicine, Division of Gastroenterology and Hepatology 2Molecular Biology Graduate Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045 Correspondence Matthew A. Burchill, University of Colorado Denver School of Medicine, Gastroenterology and Hepatology. Email: [email protected]
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol
Authors: Gurpreet Malhi, Juan Pablo Arab
Journal: Hepatology (2024)

1Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada 2Division of Gastroenterology, Department of Internal Medicine, Hepatology, and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA 3Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile Abbreviations: AIH, Autoimmune hepatitis; CBR, complete biochemical remission; 6TGN, 6-thiopurine nucleotides. Correspondence Juan Pablo Arab, Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine. 1201 E. Broad St. P.O. Box 980341, Richmond, VA 23284, USA. Email: [email protected]
PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis
Authors: Praveena Narayanan
Journal: Hepatology (2024)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Correspondence Praveena Narayanan, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. Email: [email protected]
The ultimate ensemble: Seeing the forest through the trees in alcohol-associated hepatitis
Authors: Camille A. Kezer
Journal: Hepatology (2024)

Division of Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA Correspondence Camille A. Kezer, Division of Gastroenterology and Hepatology, Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester 55905, MN, USA. Email: [email protected]
Sex chromosome evolution: hallmarks and question marks
Authors: Paul A Saunders, Aline Muyle
Journal: Molecular Biology and Evolution (2024)

Abstract Sex chromosomes are widespread in species with separate sexes. They have evolved many times independently and display a truly remarkable diversity. New sequencing technologies and methodological developments have allowed the field of molecular evolution to explore this diversity in a large number of model and nonmodel organisms, broadening our vision on the mechanisms involved in their evolution. Diverse studies have allowed us to better capture the common evolutionary routes that shape sex chromosomes; however, we still mostly fail to explain why sex chromosomes are so diverse. We review over half a century of theoretical and empirical work on sex chromosome evolution and highlight pending questions on their origins, turnovers, rearrangements, degeneration, dosage compensation, gene content, and rates of evolution. We also report recent theoretical progress on our understanding of the ultimate reasons for sex chromosomes’ existence.
Systemically injected oxygen within rapidly dissolving microbubbles improves the outcomes of severe hypoxaemia in swine
Authors: Julia Garcia Mancebo, Kristen Sack, Jay Hartford, Saffron Dominguez, Michelle Balcarcel-Monzon, Elizabeth Chartier, Tien Nguyen, Alexis R Cole, Francesca Sperotto, David M Harrild, Brian D Polizzotti, Allen D Everett, Alan B Packard, Jason Dearling, Arthur G Nedder, Simon Warfield, Edward Yang, Hart G W Lidov, John N Kheir, Yifeng Peng
Journal: Nature Biomedical Engineering (2024)
Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology
Authors: A. L. Madsen, S. Bonàs-Guarch, S. Gheibi, R. Prasad, J. Vangipurapu, V. Ahuja, L. R. Cataldo, O. Dwivedi, G. Hatem, G. Atla, M. Guindo-Martínez, A. M. Jørgensen, A. E. Jonsson, I. Miguel-Escalada, S. Hassan, A. Linneberg, Tarunveer S. Ahluwalia, T. Drivsholm, O. Pedersen, T. I. A. Sørensen, A. Astrup, D. Witte, P. Damm, T. D. Clausen, E. Mathiesen, T. H. Pers, R. J. F. Loos, L. Hakaste, M. Fex, N. Grarup, T. Tuomi, M. Laakso, H. Mulder, J. Ferrer, T. Hansen
Journal: Nature Metabolism (2024)

The genetics of β-cell function (BCF) offer valuable insights into the aetiology of type 2 diabetes (T2D)1,2. Previous studies have expanded the catalogue of BCF genetic associations through candidate gene studies3–7, large-scale genome-wide association studies (GWAS) of fasting BCF8,9 or functional islet studies on T2D risk variants10–14. Nonetheless, GWAS focused on BCF traits derived from oral glucose tolerance test (OGTT) data have been limited in sample size15,16 and have often overlooked the potential for related traits to capture distinct genetic features of insulin-producing β-cells17,18. We reasoned that investigating the genetic basis of multiple BCF estimates could provide a broader understanding of β-cell physiology. Here, we aggregate GWAS data of eight OGTT-based BCF traits from ~26,000 individuals of European descent, identifying 55 independent genetic associations at 44 loci. By examining the effects of BCF genetic signals on related phenotypes, we uncover diverse disease mechanisms whereby genetic regulation of BCF may influence T2D risk. Integrating BCF-GWAS data with pancreatic islet transcriptomic and epigenomic datasets reveals 92 candidate effector genes. Gene silencing in β-cell models highlights ACSL1 and FAM46C as key regulators of insulin secretion. Overall, our findings yield insights into the biology of insulin release and the molecular processes linking BCF to T2D risk, shedding light on the heterogeneity of T2D pathophysiology. In a genome-wide association study for traits related to pancreatic beta-cell function in 26,000 individuals, 55 independent associations mapping to 44 genetic loci are identified.
How to prepare for the next inevitable Ebola outbreak: lessons from West Africa
Authors: Henry Kyobe Bosa, Neema Kamara, Merawi Aragaw, Misaki Wayengera, Patrick D. M. C. Katoto, Chikwe Ihekweazu, Mosoka P. Fallah, Moussa Douno, Robert Kwame Agyarko, Placide Mbala, Mamadou Souncalo Traoré, Ambrose Talisuna, James Bangura, Henry G. Mwebesa, Abdoulaye Bousso, Obasanya Joshua, James Sylvester Squire, Tolbert Nyenswah, Thelma V. Nelson, Justin Maeda, Olushayo Oluseun Olu, Yonas Tegegn Woldemariam, Benjamin Djoudalbaye, Alain Ngashi Ngongo, Tajudeen Raji, Francis Chisaka Kasolo, Ibrahima Socé Fall, Ahmed Ouma Ogwell, Jane Ruth Aceng, Jean Kaseya
Journal: Nature Medicine (2024)